Member for Terrigal, Mr Adam Crouch, has welcomed the NSW Government’s announcement that a Memorandum of Understanding (MOU) has been signed with GW Pharmaceuticals to progress a major new research program for cannabis-based medicines for children with severe, drug resistant pediatric epilepsy.
Mr Crouch said many children are suffering and this announcement will provide hope for families. “This is a government showing incredible progress.
“NSW is the fi rst state in Australia to have a research programme that will provide legal and safe access to cannabis-based medicines for children suffering,” Mr Crouch said.
The MOU will facilitate: a world first phase two clinical trial in children for GW’s novel product containing the cannabinoid cannibidivarin, a compassionate access scheme for Epidiolex, and will make provision for NSW to host additional phase three trials of Epidiolex and a phase four clinical trial of Epidiolex based on phase three results.
Media release,
Oct 27, 2015
Debra Wales, Office of
Adam Crouch MP